| Title: | Frailty in COPD: an analysis of prevalence and clinical impact using UK Biobank |
| Journal: | BMJ Open Respiratory Research |
| Published: | 4 Jul 2022 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/35787523/ |
| DOI: | https://doi.org/10.1136/bmjresp-2022-001314 |
| URL: | https://bmjopenrespres.bmj.com/content/bmjresp/9/1/e001314.full.pdf |
Publication 14031
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
BACKGROUND: Frailty, a state of reduced physiological reserve, is common in people with chronic obstructive pulmonary disease (COPD). Frailty can occur at any age; however, the implications in younger people (eg, aged <65 years) with COPD are unclear. We assessed the prevalence of frailty in UK Biobank participants with COPD; explored relationships between frailty and forced expiratory volume in 1 second (FEV1) and quantified the association between frailty and adverse outcomes.</p>
METHODS: UK Biobank participants (n=3132, recruited 2006-2010) with COPD aged 40-70 years were analysed comparing two frailty measures (frailty phenotype and frailty index) at baseline. Relationship with FEV1 was assessed for each measure. Outcomes were mortality, major adverse cardiovascular event (MACE), all-cause hospitalisation, hospitalisation with COPD exacerbation and community COPD exacerbation over 8 years of follow-up.</p>
RESULTS: Frailty was common by both definitions (17% frail using frailty phenotype, 28% moderate and 4% severely frail using frailty index). The frailty phenotype, but not the frailty index, was associated with lower FEV1. Frailty phenotype (frail vs robust) was associated with mortality (HR 2.33; 95% CI 1.84 to 2.96), MACE (2.73; 1.66 to 4.49), hospitalisation (incidence rate ratio 3.39; 2.77 to 4.14) hospitalised exacerbation (5.19; 3.80 to 7.09) and community exacerbation (2.15; 1.81 to 2.54), as was frailty index (severe vs robust) (mortality (2.65; 95% CI 1.75 to 4.02), MACE (6.76; 2.68 to 17.04), hospitalisation (3.69; 2.52 to 5.42), hospitalised exacerbation (4.26; 2.37 to 7.68) and community exacerbation (2.39; 1.74 to 3.28)). These relationships were similar before and after adjustment for FEV1.</p>
CONCLUSION: Frailty, regardless of age or measure, identifies people with COPD at risk of adverse clinical outcomes. Frailty assessment may aid risk stratification and guide-targeted intervention in COPD and should not be limited to people aged >65 years.</p>
6 Keywords
- Biological Specimen Banks
- Frailty
- Humans
- Prevalence
- Pulmonary Disease, Chronic Obstructive
- United Kingdom
7 Authors
- Peter Hanlon
- James Lewsey
- Jennifer K Quint
- Bhautesh D Jani
- Barbara I Nicholl
- David A McAllister
- Frances S Mair
1 Application
| Application ID | Title |
|---|---|
| 14151 | Exploring multimorbidity in UK Biobank ? patterns of illness reporting and effects of comorbidity and multimorbidity on health outcomes |
Enabling scientific discoveries that improve human health